| FBLTX | FNBGX | FBLTX / FNBGX | |
| Total Expense Ratio | 0.03 | 0.03 | 100% |
| Annual Report Gross Expense Ratio | 0.05 | 0.03 | 167% |
| Fund Existence | 11 years | 9 years | - |
| Gain YTD | -4.315 | -3.997 | 108% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 0 | 0 | - |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 12.8B | 4.92B | 260% |
| Annual Yield % from dividends | 4.39 | 4.19 | 105% |
| Returns for 1 year | -4.73 | -4.10 | 115% |
| Returns for 3 years | -0.56 | 2.14 | -26% |
| Returns for 5 years | -35.18 | -31.41 | 112% |
| Returns for 10 years | -23.58 | N/A | - |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| FLCKX | 44.21 | 0.53 | +1.21% |
| Fidelity Leveraged Company Stock K | |||
| TBCIX | 215.21 | 1.28 | +0.60% |
| T. Rowe Price Blue Chip Growth I | |||
| GRGTX | 55.15 | -0.14 | -0.25% |
| Goldman Sachs Equity Income Inv | |||
| FIJCX | 91.57 | -0.62 | -0.67% |
| Fidelity Advisor Consumer Staples Z | |||
| RYOIX | 93.54 | -1.10 | -1.16% |
| Rydex Biotechnology Inv | |||